About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$13.11
Change (%) Stock is Down 0.07 (0.53%)
Volume4,324
Data as of 05/27/16 9:44 a.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $13.11 with a 52 week high of $24.36 and a 52 week low of $6.52.

Recent News

Natera Reports First Quarter 2016 Financial Results - 05/10/16
SAN CARLOS, Calif., May 10, 2016 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2016 and pr... More»
Natera Announces First Quarter Earnings Conference Call - 05/03/16
SAN CARLOS, Calif., May 3, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2... More»
Natera Announces the Appointment of Kimberly Martin, MD as Senior Global Medical Director, Women's Health Franchise - 04/25/16
SAN CARLOS, Calif., April 25, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced today that Kimberly Martin, MD, FRCSC, FCCMG, FACOG, FACMG has assumed ... More»
American Medical Association Grants New CPT Code for Microdeletion Testing - 03/11/16
SAN CARLOS, Calif., March 11, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced the American Medical Association (AMA) has approved Natera's applicatio... More»
Natera Reports Fourth Quarter and Fiscal Year 2015 Financial Results - 03/08/16
SAN CARLOS, Calif., March 8, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended Decem... More»

Upcoming Events

There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools